Vistagen Therapeutics (VTGN) Prepaid Assets (2011 - 2026)
Vistagen Therapeutics (VTGN) posted Prepaid Assets of $1.5 million for Q1 2026, up 4.41% sequentially from $1.5 million in Q4 2025, and down 3.39% YoY from $1.6 million in Q1 2025.
Vistagen Therapeutics (VTGN) Prepaid Assets (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Prepaid Assets for 16 years, with the latest figure at $1.5 million in Q1 2026.
- Quarterly Prepaid Assets fell 3.39% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (down 3.39% YoY) and the FY2026 annual result came in at $1.5 million, down 3.39% from the prior year.
- Prepaid Assets improved to $1.5 million in Q1 2026 per VTGN's latest filing, from $1.5 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $3.5 million in Q2 2025 and troughed at $802000.0 in Q1 2023.
- A 5-year average of $1.8 million and a median of $1.6 million in 2022 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2022 and 2023: Prepaid Assets jumped 213.55% in 2022, then sank 70.79% in 2023.
- Over 5 years, Prepaid Assets stood at $953200.0 in 2022, then soared by 55.3% to $1.5 million in 2023, then slipped by 6.71% to $1.4 million in 2024, then rose by 6.81% to $1.5 million in 2025, then grew by 4.41% to $1.5 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $1.5 million, $1.5 million, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.54 Mn |
| Dec 31, 2025 | 1.48 Mn |
| Sep 30, 2025 | 1.76 Mn |
| Jun 30, 2025 | 3.54 Mn |
| Mar 31, 2025 | 1.59 Mn |
| Dec 31, 2024 | 1.38 Mn |
| Sep 30, 2024 | 2.37 Mn |
| Jun 30, 2024 | 2.47 Mn |
| Mar 31, 2024 | 1.51 Mn |
| Dec 31, 2023 | 1.48 Mn |
| Sep 30, 2023 | 1.39 Mn |
| Jun 30, 2023 | 1.89 Mn |
| Mar 31, 2023 | 802,000.00 |
| Dec 31, 2022 | 953,200.00 |
| Sep 30, 2022 | 1.56 Mn |
| Jun 30, 2022 | 2.89 Mn |
| Mar 31, 2022 | 2.75 Mn |
| Dec 31, 2021 | 2.94 Mn |
| Sep 30, 2021 | 2.68 Mn |
| Jun 30, 2021 | 1.87 Mn |